At the news
? NEUTRALIMPACT 4/10 6-K filed Aug 7, 2026 at 07:03 ET
Purple Biotech reported Q2 2026 financial results with a net income of $0.4M driven by non-cash warrant revaluation gains, while operating loss widened to $1.3M. Cash and equivalents stood at $6.1M, providing runway through mid-2027 per management. Preclinical data for lead candidate IM1240 was presented at EACR 2026, supporting its safety and pharmacokinetic profile, but the program remains pre-clinical with clinical entry targeted for 2027. The company raised $2.3M gross via an ATM program during H1 2026, adding dilution.
- Cash and cash equivalents + short-term deposits totaled $6.1M as of June 30, 2026, down from $9.6M at Dec 31, 2025.
- Net cash used in operating activities was $5.6M for H1 2026 vs $3.5M in H1 2025.
- Operating loss for Q2 2026 was $1.3M, up from $1.2M in Q2 2025.
- Net income of $0.4M in Q2 2026 was entirely due to a $1.7M non-cash gain from warrant revaluation.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access